Objectives: Nerve growth factor (NGF) has been proposed as a urinary biomarker and previously shown to be elevated in male patients with bladder outlet obstruction (BOO) and other lower urinary tract symptoms. No published studies have examined NGF as a potential urinary biomarker in women with BOO. The aims of this prospective study were to evaluate NGF levels in urine from women with anatomic BOO resulting from pelvic organ prolapse (POP) and/or previous incontinence surgery and to measure the effect associated with surgical or conservative management.
B ladder outlet obstruction (BOO) in women can often be a diagnostic challenge that escapes simple identification. The prevalence of BOO in women had not been well studied but ranges in the literature from 2.7% to 23%. 1 The etiology of BOO in women varies widely and can include a combination of functional, neurological, and anatomic causes for obstruction. 1 Most anatomic causes for BOO in women include previous anti-incontinence surgery, pelvic organ prolapse (POP), prolapse surgery, urethral stricture, or urethral diverticulum. Many of these anatomic causes are reversible and can be treated with surgery such as urethrolysis or conservative management with the use of a pessary or intermittent catheterization.
Currently, there are no biologic markers for BOO to use in parallel with nomograms, urodynamics (UD), validated questionnaires, or quality-of-life surveys. Having a biomarker that can be easily obtained through a urine sample will be an invaluable tool to evaluate and counsel patients with lower urinary tract symptoms (LUTS) and possible BOO. In this regard, nerve growth factor (NGF) has been suggested as a diagnostic biomarker for various forms of overactive bladder and interstitial cystitis/painful bladder syndrome. 2 Previous studies support that bladder NGF plays an important role in bladder overactivity, irritative voiding symptoms, and afferent pathway plasticity after BOO such as in benign prostatic hypertrophy. 3, 4 The increased level of NGF can reduce the threshold or increase excitability in the afferent bladder fibers leading to increased bladder sensation or detrusor overactivity. 5 There is only 1 study in the literature evaluating NGF in men with BOO. 6 In this study, Liu and Kuo 6 examined 153 male patients with BOO. They concluded that NGF levels are increased in men with BOO and overactive bladder symptoms. They also showed that these levels were reduced after medical or surgical treatment of the obstruction. Nevertheless, the etiology of BOO in women differs significantly from that of men. With more women presenting with obstruction associated with POP or after incontinence surgery obstruction, there is a need for a biomarker to help facilitate the diagnosis, treatment, and prognosis of BOO in women. The aims of this prospective, Institutional Review Board approved study were to evaluate NGF levels in women with anatomic BOO resulting from POP or previous incontinence surgery and to measure the effects of surgical correction or initiation of clean intermittent catheterization (CIC).
MATERIALS AND METHODS
From January to September 2012, all female patients with LUTS referred for evaluation and management of BOO from POP or previous anti-incontinence surgery were prospectively screened for enrollment. Inclusion criteria included women older than 18 with the following voiding parameters: elevated postvoid residual (PVR) of greater than 150 mL, valsalva voiding on UD, or urinary peak flow (Qmax) of 12 mL/s or less. A control group of 10 asymptomatic age-matched female volunteers was also recruited. All women were free from urinary tract infection at the time of enrollment. The institutional review board and ethics committee of Houston Methodist Hospital approved this study. All study participants provided informed consent before the collection of urine samples. The Institutional Review Board number of our study was 0212-0029.
Urinary NGF levels were measured in 10 women with anatomic BOO and 10 asymptomatic female volunteers. At baseline, urinary NGF, urine creatinine (Cr), NGF/Cr ratio, baseline questionnaires including urinary distress inventory-6 (UDI-6) and pelvic organ prolapse distress inventory-6 (POPDI-6) uroflow, PVR, and urodynamic evaluation were evaluated. Moreover, 1 and 3 months after either surgical intervention or conservative management, urinary NGF, urine Cr, NGF/Cr ratio, uroflow, and PVR were reevaluated.
Urinary NGF-Cr Evaluation
A midstream second morning urine or random urine during the day was collected as recommended for urinary proteome analysis. 7 First morning urine collection was avoided. Urine samples were immediately placed on ice and centrifuged at 3000 rpm for 10 minutes. At least 4 aliquots (1.5 mL) of the supernatant were preserved at j80-C. One of the aliquots was used to measure the urine Cr level. 7 Urinary NGF was measured in triplicate from a second vial with an enzyme-linked immunosorbent assay using the NGF Emax ImmunoAssay System (Promega; Madison, WI). This assay is sensitive enough to detect picogram levels of NGF per milliliter of urine. The amount of NGF in each sample was calculated from the NGF standard curve. Each urinary NGF value was normalized to its corresponding Cr level, and results were determined after averaging the group values.
Statistical Analysis
A power analysis was performed with a power of 0.80 and a value of > of 0.05 based on results of a previous study by Liu and Kuo 6 looking at urinary NGF/Cr levels in men with BOO. Sample size based on this calculation was 5 patients. The NGF levels and other variables in women with BOO, before and after surgical correction or initiation of CIC, and in the control group were compared using Student t tests for continuous variables. 
RESULTS
A screening of 17 women yielded a total of 10 female patients with anatomic BOO (mean age of 66.2 [3.88] years) who were then paired with 10 healthy female control subjects (mean age of 62 [7] years). There was no statistical difference in age (P = 0.364) between the 2 groups. Nine patients had POP. Six patients had undergone a previous anti-incontinence procedure. Five patients had both POP and undergone a previous anti-incontinence procedure. Table 1 details the cause of BOO in each patient along with the subsequent treatment. Seven patients completed a preoperative UDI-6 survey with a mean score of 16.3 (1.8), and 6 patients completed a preoperative POPDI-6 survey with a mean score of 10.2 (2.6). The POPDI-6 and UDI-6 subsection scores are reported in Table 2 . The UD was obtained in 9 of the 10 patients, all with evidence of valsalva voiding. Two patients were unable to urinate. The mean max urinary flow (Qmax) for the other 7 patients was 6.3 (1.9) mL/s with Pdet at Qmax of 7.5 (4.1) cm H 2 O. Five of the 7 patients had Qmax less than 12 mL/s. The 1 patient who did not undergo UD had frank urinary retention with a PVR of 1200 mL. The mean PVR was 232 (101.23) mL.
Surgical interventions included colpocleisis in 3 patients, robotic sacrocolpopexy in 2 patients, uterosacral ligament suspension in 1 patient, sling excision and replacement in 1 patient, suprameatal urethrolysis in 1 patient, and robotic burch suspension suture takedown in 1 patient (Table 1 ). Conservative management with CIC was initiated in 1 patient. After treatment, mean PVR was reduced to 125.86 (95.94) mL (P = 0.459). The UDI-6 scores were significantly reduced from 16.3 (1.78) to 3.33 (2.4) after treatment (P = 0.01). Posttreatment Qmax was significantly increased to 12.4 (3.08) mL/s from 6.3(1.86) mL/s (P = 0.031).
The urinary NGF/Cr levels in the study patients with BOO (20.8 [4.31] pg/mg) were significantly higher (P = 0.006) than the levels in the control group (5.6 [0.65] pg/mg), as seen in Figure 1 . In addition, the level of urinary NGF showed a weak positive correlation (r 2 = 0.16) with patient-reported UDI-6 scores, as seen in Figure 2 . After treatment with release of previous anti-incontinence procedure or POP repair, the urinary NGF/Cr level significantly decreased (P = 0.009) to 6.50 (0.57) pg/mg (Fig. 1) . In 2 patients with 3 months postintervention follow-up, the urine NGF/Cr levels continued to be significantly decreased (P = 0.008) at the 3 months postoperatively (4.95 [1.85] pg/mg) compared with before intervention. Figure 3 shows a scatterplot detailing the (1) urinary NGF and (2) urinary NGF/Cr levels for each individual patient.
DISCUSSION
The results of this study showed that female patients with anatomic BOO resulting from POP and/or previous incontinence surgery had significantly higher urinary NGF/Cr levels when compared with age-matched controls. Upon correction of the obstruction, either through surgical intervention or implementation of a CIC regimen, the urinary NGF/Cr levels significantly decreased. Furthermore, the decreases in NGF/Cr levels after treatment correlated with subjective improvement in the symptoms of patients as demonstrated by decreased UDI-6 survey scores and objective improvement as demonstrated by increased flow rates. These results suggest that urinary NGF/Cr levels could potentially serve as a biomarker for the diagnosis of BOO as well as an objective assessment of the therapeutic effects of surgical or medical intervention in women.
The NGF is produced by bladder smooth muscle cells, urothelial cells, and sensory afferent neurons that innervate the urinary bladder. 8 Under normal conditions, NGF levels in the urine are low. However, increasing levels of NGF are known to be associated with bladder enlargement, sympathetic and sensory hyperinnervation, and bladder hyperactivity. 9 In addition, chemical or physical irritation, detrusor overactivity, and BOO have been shown to increase bladder inflammation, with a subsequent rise in urinary NGF levels. 10 Indeed, NGF expression has been shown to increase in an in vitro model mimicking BOO. It has been hypothesized that, through mechanical stretching, NGF expression in the bladder wall may increase leading to a reduced sensory threshold resulting in urgency or a reduced threshold for mediating detrusor hyperactivity. 11 A previous work by Liu and Kuo 12 demonstrated that urinary NGF levels were increased in men with BOO compared with control subjects and that successful long-term medical management of BOO led to decreased urinary NGF levels. However, this previous study only assessed the use of NGF as an indicator of BOO in male patients. The current study has demonstrated that these results are generalizable to women as well. We have shown that women with BOO presented elevated urinary NGF/Cr levels when compared with normal controls and that these levels significantly decrease with appropriate surgical treatment.
A recent study by Chai et al 13 looked at various urinary biomarkers before and after midurethral sling surgery for stress urinary incontinence. The urinary markers after continence surgery trial studied urinary NGF values in 150 women with stress urinary incontinence before and 1 year after midurethral sling surgery. The mean nonnormalized NGF level of 10.95 pg/mL at baseline is consistent with our study where our control patients (urinary incontinence-free healthy volunteers) had a nonnormalized NGF level of 8.2 pg/mL. Kuo et al 14 noted a mean nonnormalized NGF level of 1.52 pg/mL in their control population. When NGF levels were normalized for Cr, the Chai study had a mean urinary NGF/Cr level of 24.23 pg/mg, which is higher than our study control levels of 5.6 pg/mg. This discrepancy could be explained by variation in different baseline levels when the assay is run by different laboratories. The important thing is that the urinary NGF/Cr values for the baseline serve as a ''self'' control when assessing the impact of an intervention. Furthermore, Chai found that the urinary NGF/Cr levels increased after placement of a midurethral sling, although it was not statistically significant. This suggests that midurethral slings may be obstructive, which are consistent with our results.
Considering these results, it seems likely that NGF/Cr levels could serve as a useful biomarker in patients with signs of BOO. Although elevated NGF/Cr levels in a patient complaining of obstructive bladder symptoms would likely supplement rather than replace formal urodynamic assessment, NGF/Cr levels may replace the need for postoperative urodynamic studies, saving money while decreasing invasive testing and potential harm to patients. However, additional studies need to be performed before the establishment of NGF/Cr levels as a BOO biomarker and a routine testing modality. Specifically, it should be determined whether there is a linear relationship between the severity of bladder inflammation and obstruction and the quantitative NGF levels. Despite the current limitations, however, urinary NGF/Cr levels seem to be a promising future biomarker for use in diagnosing and evaluating BOO.
The low number of patients involved in this study was the primary limitation. Although the results of this report are consistent and significant, further information regarding the use of NGF/Cr level testing could have been gathered if the study had enrolled additional patients. Moreover, although the current investigation demonstrated elevated levels of urinary NGF/Cr in patients with BOO, with a larger patient population, the relationship between the degree of bladder obstruction severity and 
